Aflibercept approval expands treatment options for patients with ROP

Prof Anat Loewenstein, Chair, Department of Ophthalmology, Tel Aviv Medical Center (Israel), comments on the significance of the US FDA approval of aflibercept for preterm infants with retinopathy.

Sheryl Stevenson, Group Editorial Director, Ophthalmology Times Europe®: What is the importance or significance of this approval for these patients?

Prof Anat Loewenstein, Chair, Department of Ophthalmology, Tel Aviv Medical Center (Israel): I think that the approval of aflibercept for premature infants with ROP is a very significant step forward in the management of these little patients of ours.

We know that many of them have uncontrollable disease. Not all of them respond to bevacizumab and the ability of us to be able to treat them with a registered drug, FDA approved, will enhance the way we manage them.

We have good treatment with anti-VEGF therapy for ROP patients and having a registered good drug to do it with...with the results that we are of huge benefit to these patients.

Stevenson: Thank you for your insights. Always very appreciated.

Loewenstein: Thank you.

Related Videos
Younger patients often require repeat corneal crosslinking, study finds
Fluid dynamics in wet macular degeneration: How fluid type affects visual acuity
Should endocyclophotocoagulation be considered part of MIGS? Mr Ratnarajan delves in
EDOF lens tech is evolving to help more patients with intermediate vision
Fixoflex ring: Prof. Pallikaris describes how to utilise the device during IOL implantation
EURETINA leadership discusses what to expect at the 2022 Congress, outlines Women in Retina programme
Paediatric eyes repair better with scleral buckling, adults need vitrectomy only for giant retinal tear-related detachments
Clinical trials in wet AMD: Impact of central subfield thickness, volatility on visual acuity
© 2023 MJH Life Sciences

All rights reserved.